Bayer Healthcare

Rank in 2013: 10th
Community Size: 13th
Activity: 2nd
Engagement: 5th
Virality: 2nd

Bayer Healthcare jumped in the rankings this year to No. 2, with Ogilvy noting it did so "by adopting a fresher strategic approach." Bayer HealthCare is particularly active on Twitter, where it has more than 75,000 followers. Promotion around and about awareness days, including World Diabetes Day and World Stroke Day, account for many of its tweets. Bayer HealthCare also aggressively markets its annual Grants4Apps healthcare incubator program on millennial hangouts such as Twitter and Vine.

One interesting example of engagement from BayerGroup is a YouTube video it created, called "8 simple steps to cure any disease," that tackles the issue of drug development expenses in a tongue-in-cheek way. It goes through the arduous drug research and development process, quoting numbers and tossing in cheeky commentary like "Googling and Wikipedia-ing won't cut it" for research, and "no, Facebook friends won't be enough" for a clinical trial. The kicker, of course, is that €1 billion for the average development of a new drug is a huge undertaking and not actually to be taken lightly. The video's current 150,000+ views far outstrips the average 6,600 views for typical science and tech videos.

For more:
FDA approves a second placement confirmation test for Bayer's controversial Essure birth control device
Bayer draws up big sales plans for ex-Merck OTC meds
Bayer, J&J aim to protect Xarelto's market lead with focus on clinical data
Valeant can have Zoetis, Bayer says. We have our hands full already
UPDATED: Bayer, J&J touting Xarelto trial data to counteract Eliquis surge

Bayer Healthcare

Suggested Articles

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.

AstraZeneca’s Farxiga is chasing an OK to treat heart failure regardless of a diabetes diagnosis. But in the meantime, it's scored a smaller nod.

Combined with Avastin, Roche's IO med beat Bayer's standard-of-care Nexavar at stalling liver cancer progression—and helped patients live longer, too.